½ÃÀ庸°í¼­
»óǰÄÚµå
1342789

¼¼°èÀÇ ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ ½ÃÀå : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2023-2030³â)

Global Drug Device Combination Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 128 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ(Drug Device Combination) ½ÃÀå ¼ö¿ä´Â 2022³â 2,203¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. 2030³â 5,048¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀ̸ç, 2023³âºÎÅÍ 2030³â±îÁö 10.92%ÀÇ CAGR ¼ºÀå·üÀ» º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ ½Ã½ºÅÛÀº ¾à¹° Àü´Þ ¹× »ý¹°ÇÐÀû ¼ººÐÀ» ÅëÇÕÇÏ¿© ¾à¹° Àü´ÞÀ» °³¼±Çϱâ À§ÇØ ¿©·¯ ÀÇ·á±â±â¸¦ ÅëÇÕÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç°Àº ÀüÅëÀûÀÎ ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡¼­ ÀϹÝÀûÀ¸·Î º¼ ¼ö ¾ø´Â ¿øÇÏ´Â È¿°ú¸¦ ¾ò±â À§ÇÑ ÅëÇÕ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¶ÇÕ Á¦Ç°Àº ¾ÈÀü°ú ǰÁú ±âÁØÀ» À¯ÁöÇϱâ À§ÇØ ¾ö°ÝÇÑ ±ÔÁ¦ ÀýÂ÷¸¦ °ÅÃÄ¾ß ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç°¿¡´Â ƯÁ¤ ±âÁØÀ» °¡Áø ´Ù¾çÇÑ ±ÔÁ¦ ±×·ì ±¸¼º ¿ä¼Ò°¡ ³»ÀåµÇ¾î ÀÖÀ¸¹Ç·Î ±ÔÁ¦ ´ç±¹ Çã°¡ Áß ÀϰüµÇ°Ô ¸ð´ÏÅ͸µµË´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº ÀÓÇöõÆ® ±â¼ú µî ´Ù¾çÇÏ°í °íµµ·Î º¹ÀâÇÑ ÀÓ»ó ±â¼ú°ú ±â´É Çâ»óÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

½ÃÀå ¿ªÇÐ:

±× °á°ú, ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕÀ¸·Î ÀÎÇÑ °æÁ¦Àû ÀÌÁ¡Àº ¼¼°èÀûÀÎ Àαâ¿Í °ü·Ã¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÇ·á±â±â »ê¾÷ÀÇ ±Þ¼ÓÇÑ È®´ë, ¸¸¼ºÁúȯÀÇ ¸¸¿¬ È®´ë, ½ÅÁ¦Ç° Ãâ½Ã¼öÀÇ ±ÞÁõÀÌ ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ Á¦Ç° ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖµÈ ÀÌÀ¯ÀÔ´Ï´Ù. °Ô´Ù°¡ Á¤ºÎ¿Í ¹Î°£ ÀÇÇבּ¸ Áö¿ø, R&D ÅõÀÚ Áõ°¡, ½ÅÈï±¹ °Ç°­°ü¸® ÀÇ½Ä Áõ°¡ µîÀÌ ¼¼°èÀÇ ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ¸î °¡Áö ÀÌÀ¯ÀÔ´Ï´Ù. ±×·¯³ª °í°¡ ¼ö¼ú ºñ¿ë°ú °æ°ú °üÂû, ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ Á¦Ç° Á¦ÇÑÀûÀÎ ±ÔÁ¦ Á¦µµ´Â ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¶»ç º¸°í¼­´Â Porter's Five Forces ºÐ¼® ¸ðÇü, ½ÃÀå ¸Å·Â ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°è ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØÀÇ °æÀïµµ¸¦ Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ µµ±¸´Â ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ ½ÃÀåÀÇ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ »ê¾÷ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ Àü¹ÝÀûÀÎ Á¢±ÙÀ» Á¦°øÇÕ´Ï´Ù.

Áö¿ª ºÐ¼® :

ÀÌ ¼½¼ÇÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÀǾàǰ ¹× ÀÇ·á±â±â Á¶ÇÕ ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ¸ðµç ÁÖ¿ä Áö¿ª °³º° ¿ëµµ, ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÁßÁ¡À» µÓ´Ï´Ù.

¿äûÀÌ ÀÖ´Ù¸é ÀúÈñ¿¡°Ô ¿¬¶ô ¹Ù¶ø´Ï´Ù. ´ç»ç ¼³¹®Á¶»çÆÀÀº °í°´ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ½ÃÀå ÇöȲ

Á¦3Àå ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ-»ê¾÷ ºÐ¼®

  • ¼Ò°³ : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø ¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦ ¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼® ºÐ¼®
  • ½ÃÀå ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·á °¡°Ý µ¿Çâ
  • ÀáÀçÀû ±¸¸ÅÀÚ ¸ñ·Ï
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå COVID-19 ¹ß»ý ¿µÇ⠺м®

Á¦6Àå ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Á¦Ç°º° ÁÖ¿ä ¿ä¾à
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Á¦Ç°º° ºÐ¼®
  • ÁÖÀÔ ÆßÇÁ(¿ë·®Çü, µð½ºÆ÷Àúºí, ÁÖ»ç±â, ¿Ü·¡Çü, ¸Å¸³Çü, Àν¶¸°)
  • Á¤Çü¿Ü°ú¿ë Á¶ÇÕÁ¦Ç°(°ñÀÌ½Ä ÀÓÇöõÆ®, Ç×»ý¹°Áú °ñ ½Ã¸àÆ®)
  • ±¤¼±¿ªÇпä¹ý±â±â
  • °æÇÇ ÆÐÄ¡
  • ¾àÁ¦ ¿ëÃâ ½ºÅÙÆ®(°üµ¿¸Æ ½ºÅÙÆ®, ¸»ÃÊ Ç÷°ü ½ºÅÙÆ®)
  • »óó Äɾî Á¦Ç°
  • ÈíÀÔ±â(µå¶óÀÌ ÆÄ¿ì´õ, ºÐ¹«±â, Á¤·® ºÐ¹«±â)
  • Ç×±Õ Ä«Å×ÅÍ(ºñ´¢±â, ½ÉÀåÇ÷°ü, ±âŸ)
  • ±âŸ

Á¦7Àå ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼Ò°³
  • ºÏ¹Ì ¸ÅÃ⠺м®
    • ÁÖ¿ä ¿ä¾à, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ¸ÅÃ⠺м®
    • ÁÖ¿ä ¿ä¾à, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ¸ÅÃ⠺м®
    • ÁÖ¿ä ¿ä¾à, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ¸ÅÃ⠺м®
    • ÁÖ¿ä ¿ä¾à, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¸ÅÃ⠺м®
    • ÁÖ¿ä ¿ä¾à, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿, ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ ±â¾÷ °æÀï ±¸µµ

  • ÀǾàǰ ÀÇ·á±â±â Á¶ÇÕ ½ÃÀå °æÀï
  • Á¦ÈÞ, Çù·Â, ÇÕÀÇ
  • ÇÕº´, Àμö
  • ½ÅÁ¦Ç° ÇöȲ
  • ±âŸ °³¹ß

Á¦9Àå ±â¾÷ ÇÁ·ÎÇÊ

  • »óÀ§ ±â¾÷ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Abbott
  • Terumo Corporation
  • Stryker Corporation
  • Mylan NV
  • Medtronic
  • Allergan plc
  • Boston Scientific Corporation
  • Novartis AG
  • CR Bard
  • Teleflex Incorporated
  • WL Gore& Associates Inc.
NJH 23.10.06

The global demand for Drug Device Combination Market is presumed to reach the market size of nearly USD 504.88 BN by 2030 from USD 220.35 BN in 2022 with a CAGR of 10.92% under the study period 2023 - 2030.

Drug device combination systems integrate some medical equipment with medications or biological components to improve drug delivery. These products function as a single entity to achieve desired effectiveness, which is generally absent in conventional drug delivery systems. Combination products must undergo a rigorous regulatory procedure to maintain safety and quality standards. Because these items incorporate components from various regulatory groups with specific criteria, they are consistently monitored during regulatory clearances. These solutions are expected to represent a diverse, highly complex clinical technology and functional enhancements in implant technology.

MARKET DYNAMICS:

As a result, the financial benefits of drug-device combination products are increasing in popularity and relevance worldwide. Rapid expansion in the medical device industry, growing chronic illness prevalence, and an upsurge in the number of new product releases are the primary reasons expected to drive demand for drug-device combination products. Furthermore, government and private support for medical research increased R&D investment, and increased healthcare awareness in emerging nations are a few reasons anticipated to drive the worldwide medication device combination market. However, high operating expenses and follow-ups, as well as a restrictive regulatory system concerning drug-device combination products, can hamper the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of drug device combination. The growth and trends of drug device combination industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the drug device combination market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Infusion Pumps (Volumetric, Disposables, Syringes, Ambulatory, Implantable, Insulin)
  • Orthopedic Combination Products (Bone Graft Implants, Antibiotic Bone Cement)
  • Photodynamic Therapy Devices
  • Transdermal Patches
  • Drug Eluting Stents (Coronary Stents, Peripheral Vascular Stents)
  • Wound Care Products
  • Inhalers (Dry Powder, Nebulizers, Metered Dose)
  • Antimicrobial Catheters (Urological, Cardiovascular, Others)
  • Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Drug Device Combination market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the drug device combination market include Abbott, Terumo Corporation, Stryker Corporation, Mylan N.V., Medtronic, Allergan plc, Boston Scientific Corporation, Novartis AG, C.R. Bard, Teleflex Incorporated, W. L. Gore & Associates Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . DRUG DEVICE COMBINATION - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL DRUG DEVICE COMBINATION MARKET ANALYSIS BY PRODUCT

  • 6.1 Overview by Product
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Product
  • 6.4 Infusion Pumps (Volumetric, Disposables, Syringes, Ambulatory, Implantable, Insulin) Historic and Forecast Sales by Regions
  • 6.5 Orthopedic Combination Products (Bone Graft Implants, Antibiotic Bone Cement) Historic and Forecast Sales by Regions
  • 6.6 Photodynamic Therapy Devices Historic and Forecast Sales by Regions
  • 6.7 Transdermal Patches Historic and Forecast Sales by Regions
  • 6.8 Drug Eluting Stents (Coronary Stents, Peripheral Vascular Stents) Historic and Forecast Sales by Regions
  • 6.9 Wound Care Products Historic and Forecast Sales by Regions
  • 6.10. Inhalers (Dry Powder, Nebulizers, Metered Dose) Historic and Forecast Sales by Regions
  • 6.11 Antimicrobial Catheters (Urological, Cardiovascular, Others) Historic and Forecast Sales by Regions
  • 6.12 Others Historic and Forecast Sales by Regions

7 . GLOBAL DRUG DEVICE COMBINATION MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1. Overview, Historic and Forecast Sales Analysis
    • 7.3.2. North America By Segment Sales Analysis
    • 7.3.3. North America By Country Sales Analysis
    • 7.3.4. United State Sales Analysis
    • 7.3.5. Canada Sales Analysis
    • 7.3.6. Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1. Overview, Historic and Forecast Sales Analysis
    • 7.4.2. Europe by Segment Sales Analysis
    • 7.4.3. Europe by Country Sales Analysis
    • 7.4.4. United Kingdom Sales Analysis
    • 7.4.5. France Sales Analysis
    • 7.4.6. Germany Sales Analysis
    • 7.4.7. Italy Sales Analysis
    • 7.4.8. Russia Sales Analysis
    • 7.4.9. Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1. Overview, Historic and Forecast Sales Analysis
    • 7.5.2. Asia Pacific by Segment Sales Analysis
    • 7.5.3. Asia Pacific by Country Sales Analysis
    • 7.5.4. China Sales Analysis
    • 7.5.5. India Sales Analysis
    • 7.5.6. Japan Sales Analysis
    • 7.5.7. South Korea Sales Analysis
    • 7.5.8. Australia Sales Analysis
    • 7.5.9. Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1. Overview, Historic and Forecast Sales Analysis
    • 7.6.2. Latin America by Segment Sales Analysis
    • 7.6.3. Latin America by Country Sales Analysis
    • 7.6.4. Brazil Sales Analysis
    • 7.6.5. Argentina Sales Analysis
    • 7.6.6. Peru Sales Analysis
    • 7.6.7. Chile Sales Analysis
    • 7.6.8. Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1. Overview, Historic and Forecast Sales Analysis
    • 7.7.2. Middle East & Africa by Segment Sales Analysis
    • 7.7.3. Middle East & Africa by Country Sales Analysis
    • 7.7.4. Saudi Arabia Sales Analysis
    • 7.7.5. UAE Sales Analysis
    • 7.7.6. Israel Sales Analysis
    • 7.7.7. South Africa Sales Analysis
    • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE DRUG DEVICE COMBINATION COMPANIES

  • 8.1. Drug Device Combination Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9 . COMPANY PROFILES OF DRUG DEVICE COMBINATION INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Abbott
    • 9.3.1. Company Overview
    • 9.3.2. Company Revenue
    • 9.3.3. Products
    • 9.3.4. Recent Developments
  • 9.4. Terumo Corporation
    • 9.4.1. Company Overview
    • 9.4.2. Company Revenue
    • 9.4.3. Products
    • 9.4.4. Recent Developments
  • 9.5. Stryker Corporation
    • 9.5.1. Company Overview
    • 9.5.2. Company Revenue
    • 9.5.3. Products
    • 9.5.4. Recent Developments
  • 9.6. Mylan N.V.
    • 9.6.1. Company Overview
    • 9.6.2. Company Revenue
    • 9.6.3. Products
    • 9.6.4. Recent Developments
  • 9.7. Medtronic
    • 9.7.1. Company Overview
    • 9.7.2. Company Revenue
    • 9.7.3. Products
    • 9.7.4. Recent Developments
  • 9.8. Allergan plc
    • 9.8.1. Company Overview
    • 9.8.2. Company Revenue
    • 9.8.3. Products
    • 9.8.4. Recent Developments
  • 9.9. Boston Scientific Corporation
    • 9.9.1. Company Overview
    • 9.9.2. Company Revenue
    • 9.9.3. Products
    • 9.9.4. Recent Developments
  • 9.10. Novartis AG
    • 9.10.1. Company Overview
    • 9.10.2. Company Revenue
    • 9.10.3. Products
    • 9.10.4. Recent Developments
  • 9.11. C.R. Bard
    • 9.11.1. Company Overview
    • 9.11.2. Company Revenue
    • 9.11.3. Products
    • 9.11.4. Recent Developments
  • 9.12. Teleflex Incorporated
    • 9.12.1. Company Overview
    • 9.12.2. Company Revenue
    • 9.12.3. Products
    • 9.12.4. Recent Developments
  • 9.13. W. L. Gore & Associates Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Company Revenue
    • 9.13.3. Products
    • 9.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦